Our research focuses on elucidating signal pathways from the surface into the interior of a cell in the context of cancer and metastasis formation. We are especially interested in so-called Receptor Tyrosine Kinases (RTKs) and their downstream signaling cascades. Our group was engaged in the preclinical development of Tyrosine Kinase Inhibitors (TKIs) in the department of Prof. Dr. Axel Ullrich at the Max-Planck-Institute of Biochemistry in Matrinsried and managed to develop and license drug candidates to the pharmaceutical industry.
Currently, we aim to block the activity of the Receptor Tyrosine Kinase AXL, being important in drug resistance in lung cancer and metastasis formation in breast cancer. An important aspect of our work is the identification and validation of predictive in vitro and in vivo models for tumor metastasis formation.The analysis of the TAM-RTK family signaling, the identification of biomarkers and mechanisms of resistance, associated with the therapeutic use of AXL inhibitors, are thereby of particular interest.
The goal is to develop synthetically lethal drug combinations by analysis of signaling cascades and nodes, avoiding drug resistance formation. This is of significant clinical importance as the majority of patients receiving targeted anti-cancer therapies relapse with in the first year of therapy. Resistance formation displays the major problem of targeted therapies and limits their success rate dramatically.
We are open-minded for strategic collaborations to improve the success rate of cancer therapies in the future. Therefore, we also invite interested colleagues to join our team. If you have any further comments or questions do not hesitate to contact us.